Novocure (NSDQ:NVCR) said today it inked a $15 million licensing agreement with Shanghai-based biopharma company Zai Lab to offer its Optune technology on the Chinese market and accelerate clinical trial enrollment in the region.
The Optune device delivers low-intensity, intermediate frequency, alternating electric fields, called “Tumor Treating Fields,” to inhibit cancer cell replication.
Read the whole story on our sister site, Drug Delivery Business News
